IP Library Granted Patent US 7,718,790
Granted Patent B2
US 7,718,790 · App. 11/686,499 · Granted May 18, 2010

Kit for assessing mitochondrial toxicity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,718,790
App. No.
11/686,499
Granted
May 18, 2010
Kind
B2
Abstract

Processes and methods for the simultaneous quantification of nucleic acids in diseased cells that are based on real-time PCR are provided. The real-time PCR protocol is an excellent tool for reliable quantification of in vitro drug screening and evaluation protocols to determine the efficacy of potential anti-viral agents. Quantification using these simultaneous PCR cycle threshold (Ct) detection techniques during one-step real-time RT-PCR (Applied Biosystems, CA) eliminates the variability resulting from quantification of end-point RT-PCR products. In addition, the mitochondrial toxicity assay is an added tool to assess potential side-effects for these chemotherapeutic agents.

Claims (21)

1. A kit for assessing mitochondrial toxicity of a compound, comprising

a mixture of oligonucleotides comprising

at least one first primer set that provides a first detectable signal on the occurrence of amplification of mitochondrial nucleic acid; and

at least one second primer set that provides a second detectable signal on the occurrence of amplification of host nuclear nucleic acid;

wherein the second primer set comprises the primers of SEQ ID No. 1 and SEQ ID No. 2.

2. The kit according to claim 1 further comprising a probe of SEQ ID No. 3 comprising a reporter molecule and a quencher molecule.

3. The kit according to claim 2 , wherein the reporter molecule is FAM and the quencher molecule is TAMRA.

4. The kit according to claim 1 , wherein the first primer set comprises the primers of SEQ ID No. 19 and SEQ ID No. 20.

5. The kit according to claim 4 further comprising a probe of SEQ ID No. 21 comprising a reporter molecule and a quencher molecule.

6. The kit according to claim 5 , wherein the reporter molecule is TET and the quencher molecule is TAMRA.

7. A kit for assessing mitochondrial toxicity of a compound, comprising

a mixture of oligonucleotides comprising

at least one first primer set that provides a first detectable signal on the occurrence of amplification of mitochondrial nucleic acid; and

at least one second primer set that provides a second detectable signal on the occurrence of amplification of host nuclear nucleic acid;

wherein the first primer set comprises the primers of SEQ ID No. 19 and SEQ ID No. 20.

8. The kit according to claim 7 , wherein the second primer set comprises the primers of SEQ ID No. 1 and SEQ ID No. 2.

9. The kit according to claim 8 further comprising a probe of SEQ ID No. 3 comprising a reporter molecule and a quencher molecule.

10. The kit according to claim 9 , wherein the reporter molecule is FAM and the quencher molecule is TAMRA.

11. The kit according to claim 7 , wherein the first primer set comprises the primers of SEQ ID No. 19 and SEQ ID No. 20.

12. The kit according to claim 11 further comprising a probe of SEQ ID No. 21 comprising a reporter molecule and a quencher molecule.

13. The kit according to claim 12 , wherein the reporter molecule is TET and the quencher molecule is TAMRA.

Assignments (3)
CERTIFICATE OF DOMESTICATION OF PHARMASSET, LTD. Recorded Mar 8, 2013
From: PHARMASSET, LTD.
To: PHARMASSET, INC.
Reel/Frame 029943/0744 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2013
From: STUYVER, LIEVEN; OTTO, MICHAEL J.
To: PHARMASSET LTD.
Reel/Frame 029955/0389 →
CHANGE OF NAME Recorded Apr 20, 2012
From: PHARMASSET, INC.
To: GILEAD PHARMASSET LLC
Reel/Frame 028081/0686 →